pharmaceutical daily

J&J answers allegations over vaccine problems

J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.

In its press release, J&J stated that the quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorized to manufacture drug substance for its COVID-19 vaccine.

This batch was never advanced to the filling and finishing stages of our manufacturing process, the company said.

Also, J&J noted that it still expects to deliver COVID-19 vaccine at a rate of more than one billion doses by the end of 2021.

J&J delivered more than 20 million single-shot vaccines for the United States by the end of March.

 

Exit mobile version